VX20-147-006
23 evidence topics · 2 sources
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2024-08-02” |
| Primary completion (actual) | “2024-12-20” |
| Study completion (actual) | “2024-12-20” |
| First posted | “2024-07-31” |
| Last update posted | “2025-01-20” |
| Other study ID numbers | “VX20-147-006” |
Study locations in the registry record
“This study has 3 locations” (opens the source at this quote in a new tab)
“Miami, Florida, United States, 33136” (opens the source at this quote in a new tab)
“St. Petersburg, Florida, United States, 33705” (opens the source at this quote in a new tab)
“San Antonio, Texas, United States, 78215” (opens the source at this quote in a new tab)
Presentation at the NKF 2026 Spring Clinical Meetings
Study design
Phase 1, open-label, single-dose design with matched healthy participants
Design details in the registry record
| Field | Registry entry |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Comparison with matched healthy participants
Eligibility criteria
Child-Pugh classes and matching of healthy participants
Key exclusion criteria in the registry record
Age range and healthy volunteers
| Field | Registry entry |
|---|---|
| Ages eligible | “18 Years to 75 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Arms in the registry record
“Experimental: Cohort 1: Mild Hepatic Impairment” (opens the source at this quote in a new tab)
“Experimental: Cohort 2: Matched Healthy Participants” (opens the source at this quote in a new tab)
“Experimental: Cohort 3: Moderate Hepatic Impairment” (opens the source at this quote in a new tab)
“Experimental: Cohort 4: Matched Healthy Participants” (opens the source at this quote in a new tab)
“Tablet for oral administration.” (opens the source at this quote in a new tab)
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Registered primary and secondary outcomes
Hepatic metabolism as the primary elimination pathway
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “36” |
Enrollment reported in the congress abstract
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Exposure in mild or moderate hepatic impairment compared with healthy matches
Higher exposure in one participant with a Child-Pugh score of 9
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Safety in the renal and hepatic impairment studies
Study limitations
Summary: study limitations
VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.